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Are patients with systemic lupus erythematosus 
at increased risk for COVID-19?
The global health emergency generated by the SARS- CoV-2 
outbreak has complicated the management of patients with 
comorbidities, which together with old age seem to be the stron-
gest predictor of mortality from COVID-19.1 We read with great 
interest the letter published by Mathian and colleagues about 
the clinical course of COVID-19 in patients with systemic lupus 
erythematosus (SLE) treated with hydroxychloroquine.2 Their 
preliminary data seem to suggest a particularly high incidence 
of severe and even fatal cases of infection, confirming that, 
despite ongoing treatment with antimalarial drugs, patients with 
SLE have a high risk of unfavourable course during the current 
pandemic.
The critical point that remains to be clarified at present is the 
real incidence of COVID-19 in patients with SLE, regardless of 
the current treatment. Being operative in the maximum epicentre 
of the outbreak in Italy (Milan, Lombardy), we have had to face 
in these weeks the emergency related to the management of such 
a fragile population and we have tried to obtain from our cohort 
of patients information useful to solve the outstanding issues. 
In particular, between 25 February and 10 April we circulated 
a survey that explored the frequency of nasopharyngeal swabs 
positive for COVID-19, the onset of suspicious symptoms due 
to viral infection (fever >37.5°C, cough, dyspnoea) and the 
impact of the pandemic on the behaviour and treatment of our 
patients. The survey was administered face to face to all patients 
who attended an outpatient visit or by telephone to those who 
missed a scheduled visit during the period under examination. 
The study population encompassed more than 900 patients, 
including 62 (91% females, mean age 44.1 years) with SLE and 
a mean disease duration of 12.6 years. About half of the patients 
(51.6%) were treated with biological drugs (26 belimumab and 
6 rituximab), 30 (48.3%) were receiving hydroxychloroquine 
while another 20 were taking another conventional synthetic 
disease- modifying drug (7 methotrexate, 11 mycophenolate, 2 
azathioprine). Forty- six (74.6%) also took corticosteroids (28 
at a dose greater than 5 mg/day). No cases of nasopharyngeal 
swab positivity were observed, while eight patients (including 
five on hydroxychloroquine) reported symptoms consistent with 
a viral infection, rapidly resolving without specific treatment. 
Only three patients reported contact with confirmed cases of 
COVID-19 and none of them developed suspicious symptoms. 
None of the patients changed their current rheumatological 
therapy and 93.5% defined their disease as stable during the 
entire period under review. Overall, therefore, the impact of 
COVID-19 in our patients with SLE was very low, in line with 
the low burden we observed in the rest of our cohort with inflam-
matory arthritis.3 The adoption of strict rules for the prevention 
of contagion, such as the use of face masks, homeworking and 
social distancing, was reported by almost all patients (95%). 
This approach, likely induced by the rheumatic disease itself, 
has probably played a decisive role in reducing the incidence 
of COVID-19 among our patients.4 Noteworthy, the majority 
of patients included had a long- term disease and were therefore 
already used to adopt measures to minimise the infectious risk 
before the COVID-19 outbreak.
In conclusion, our preliminary data, although still limited in 
number, do not seem to suggest an increased risk of SARS- CoV-2 
infection for patients with SLE. Therefore, while considering the 
severe course of COVID-19 reported in SLE, our data support 
rheumatologists in encouraging patients to maintain the ongoing 
treatment to avoid dangerous flare- ups of the disease and to 
strictly enforce the rules for prevention of infection.
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